OncoMatch/Clinical Trials/NCT07239245
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Is NCT07239245 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for resectable hepatocellular carcinoma with high risk of recurrence.
Treatment: Atezolizumab · Bevacizumab — This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Grade: Grade 3Grade 4
Initially resectable with high-risk recurrence factors. High-risk features for resected patients include tumor size >5 cm, tumor number >3, vascular invasion (microvascular invasion or macrovascular invasion - Vp1/Vp2 - of the portal vein) and poor tumor differentiation (defined as Grade 3 or 4).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: locoregional or systemic treatment
No prior locoregional or systemic treatment for HCC
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Lab requirements
Liver function
child-pugh a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify